Technical analysis of Halozyme Therapeutics, Inc. (HALO): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20).
Price Performance
| 1 month | +3.38% |
| 3 months | +58.19% |
| Year-to-date | +61.13% |
| 1 year | +43.04% |
| 3 years | +177.27% |
52-Week Range
| 52-week High | $111.15 |
| 52-week Low | $61.23 |
| Avg Volume (90d) | 1.9M |
Technical Indicators
| SMA 50 | $94.73 |
| SMA 200 | $75.48 |
| Beta | 1.03 |
| 30-day Volatility (annualised) | 57.1% |
| Price vs SMA 50 | +14.5% |
| Price vs SMA 200 | +43.7% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $65.19 | |
| 2025-11 | $71.40 | +9.5% |
| 2025-12 | $67.30 | -5.7% |
| 2026-01 | $71.71 | +6.6% |
| 2026-02 | $69.53 | -3.0% |
| 2026-03 | $64.63 | -7.0% |
| 2026-04 | $63.66 | -1.5% |
| 2026-05 | $66.54 | +4.5% |
| 2026-06 | $78.27 | +17.6% |
| 2026-07 | $82.54 | +5.5% |
| 2026-08 | $106.49 | +29.0% |
| 2026-09 | $108.44 | +1.8% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-15 | | |
| 2026-09-15 | | |
| 2026-09-15 | | |
| 2026-09-15 | | |
| 2026-09-15 | | |
| 2026-09-15 | | $344M |
Price
| Price | $108.44 |
| Market Cap | $12.9B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 30.18 |
| Price / Book | 86.81 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 14.95 |
| Current Ratio | 2.71 |